Cardiovascular polypill may not work in UK

Using the polypill in the UK could harm patient care and increase side-effects, a leading cardiovascular GP says.

The warning comes as the first polypill trial found it cut heart disease risk by a quarter.

The trial, of 2,053 people aged 45-80 with no cardiovascular disease, found it cut BP, heart rate and LDL cholesterol.

The polypill, which contains hydrocholorothiazide, atenolol, ramipril, simvastatin and aspirin, was tolerable and there was no evidence that tolerability fell as the number of active components per pill increased.

But North Yorkshire GP Dr Terry McCormack, former Primary Care Cardiovascular Society chairman, said components of polypills may harm some patients. 'Drugs need to be tailored to the needs of the individual patient,' he added.

sanjay.tanday@haymarket.com

  • Lancet Online 2009

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus